Fuzuloparib Plus Arsenic Trioxide in Patients With Platinum Resistance Relapsed Ovarian Cancer
Latest Information Update: 28 Jan 2022
At a glance
- Drugs Arsenic trioxide (Primary) ; Fuzuloparib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 23 Jan 2022 Planned End Date changed from 1 Jan 2023 to 1 Jan 2025.
- 23 Jan 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2024.
- 06 Oct 2021 Planned number of patients changed from 66 to 50.